Chul Kim is an Oncology physician affiliated with United States Naval Research Laboratory. OpenAlex indexes 116 publications with 2,077 citations (h-index 22); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3800 Reservoir Rd NW
Washington, DC 200072113
Telephone
202-444-2223Provider last certified this registry record 13 Jul 2024.
Clinical trials
- A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Sponsor: Georgetown University
- MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
Sponsor: Georgetown University
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Sponsor: Georgetown University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim International GmbHProgram year202510 payments$12,583openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202515 payments$10,724openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202516 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
24.8%Opioid Agonist10%Oxycodone Hcl100%Part D≥11 patientsGabapentinoids6.8%Gabapentin100%Part D≥13 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21.6%Corticosteroid10.9%Prednisone100%Part D≥20 patientsSerotonin-3 Receptor Antagonist8.1%Ondansetron Hcl100%Part D≥19 patients+ 1 more class in this area
Cancer & immunology
17.2%Kinase inhibitor17.2%Tagrisso72%Erlotinib Hcl28%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- National Capital Area (NCA) NCI Community Oncology Research Program (NCORP)
Georgetown University
FY2026$567,929UG1CA239758 - National Capital Area (NCA) NCI Community Oncology Research Program (NCORP)
Georgetown University
FY2025$470,756UG1CA239758
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”